Drug updated on 10/30/2023
|Tablet (oral; 20 mg)
|Sodium-glucose co-transporter 2 (SGLT2) inhibitors
|Ongoing and Completed Studies
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Product Monograph / Prescribing Information
|Brenzavvy (bexagliflozin) Prescribing Information.
|TheracosBio LLC, Marlborough, MA
Systematic Reviews / Meta-Analyses
|Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
|Diabetes Obesity, and Metabolism: A Journal of Pharmacology and Therapeutics
|A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes
|Annals of Pharmacotherapy
|Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review.
|International Urology and Nephrology
|Meta-analysis Addressing the Cardiovascular Safety of Bexagliflozin in Patients With Type 2 Diabetes Mellitus
|The American Journal of Cardiology